<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Hepatitis C virus infection has been for several decades the major cause of cirrhosis and its complications worldwide. However, an arsenal of new and highly effective oral direct-acting antiviral drugs has changed the course of HCV treatment. The effects of HCV elimination are broad and include an overall reduction in mortality in patients with advanced fibrosis, a reduction of the risk of HCC in patients with advanced fibrosis and a reduction in extrahepatic manifestations including HCV-related non-Hodgkin’s lymphoma, other lymphoproliferative disorders and cryoglobulinemic vasculitis. Fibrosis regression is associated with a broad clinical benefit and remains an important therapeutic target in HCV patients who have obtained RSV.</p>
</abstract>

Hepatitis C virus infection has been for several decades the major cause of cirrhosis and its complications worldwide. However, an arsenal of new and highly effective oral direct-acting antiviral drugs has changed the course of HCV treatment. The effects of HCV elimination are broad and include an overall reduction in mortality in patients with advanced fibrosis, a reduction of the risk of HCC in patients with advanced fibrosis and a reduction in extrahepatic manifestations including HCV-related non-Hodgkin’s lymphoma, other lymphoproliferative disorders and cryoglobulinemic vasculitis. Fibrosis regression is associated with a broad clinical benefit and remains an important therapeutic target in HCV patients who have obtained RSV.

The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment

University of Medicine and Pharmacy “Grigore T. Popa”

Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Hepatitis C virus infection has been for several decades the major cause of cirrhosis and its complications worldwide. However, an arsenal of new and highly...

The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment

Publié en ligne: 10 avr. 2022

Pages: 53 - 59

DOI: https://doi.org/10.2478/inmed-2022-0197

Mots clés
hepatitis C virus, fibrosis, cirrhosis, oral direct-acting antiviral drugs

© 2022 Oana Irina Gavril et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The Evolution of Liver Fibrosis in Patients with Viral C Infection Post Oral Antiviral Treatment

Publié en ligne: 10 avr. 2022

Pages: 53 - 59

DOI: https://doi.org/10.2478/inmed-2022-0197

Mots cléshepatitis C virus, fibrosis, cirrhosis, oral direct-acting antiviral drugs

© 2022 Oana Irina Gavril et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
hepatitis C virus, fibrosis, cirrhosis, oral direct-acting antiviral drugs